BofA raised the firm’s price target on Tenet Healthcare (THC) to $230 from $225 and keeps a Buy rating on the shares. BofA views the increase in capital expenditures as a bullish sign of Tenet’s view on demand in its markets, given it is happening in front of enrollment pressures on exchanges and Medicaid, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
